Anzeige
Mehr »
Montag, 07.07.2025 - Börsentäglich über 12.000 News
EchoIQ von 3 Analysehäusern als "Best-in-Class" bewertet - Kurszielpotenzial von über 200?%
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
125 Leser
Artikel bewerten:
(0)

Elsevier's Care Planning Wins 2019 KLAS Category Leader Award

For the third year in a row, global evidence-based solution recognized in "Clinical Decision Support - Care Plans/Order Sets" category

PHILADELPHIA, Feb. 4, 2019 /PRNewswire/ --

Elsevier, the information analytics business specializing in science and health, announced today that Elsevier's Care Planning was named a 2019 Category Leader for the "Clinical Decision Support - Care Plans/Order Sets" category by KLAS, the research firm which specializes in monitoring and reporting the performance of healthcare vendors.

Elsevier Logo

Elsevier will showcase Care Planning and its other decision support solutions at Booth #3331 at the Healthcare Information and Management Systems Society (HIMSS) 2019 annual meeting in Orlando, Florida, February 12-14, 2019. For more information on what Elsevier is showcasing at HIMSS, and to reserve your spot for Elsevier's virtual panel discussion, please go here.

Elsevier's Care Planning placed at the top of the "Clinical Decision Support - Care Plans/Order Sets" category. A Category Leader designation is reserved for use in select markets in which at least two products meet a minimum level of KLAS Konfidence. Like Best in KLAS winners, vendors awarded a Category Leader designation stand out for helping healthcare organizations deliver quality patient care. The winners included in the 2019 Best in KLAS: Software and Services report were determined after more than 30,000 interviews with health systems and payers.

"It is an honor to be recognized by KLAS as a Category Leader for the third year in a row, and we are proud of the collaboration with our customers that made this possible," said Dr. John Danaher, President, Clinical Solutions, Elsevier. "Elsevier is committed to enhancing interprofessional collaboration, advancing practice, and improving patient outcomes by delivering high quality evidence-based content and workflow tools at the point of care."

Elsevier's Care Planning is the industry's only EHR-based care planning solution that combines the patient story, more than 600 evidence-based clinical practice guidelines and standardized assessments into one patient-centered plan of care across all care settings and disciplines. Clinicians can apply the evidence, at the point of care, to support decision making and improve patient outcomes.

"Category Leaders are committed to providing the very best technology, service, and guidance to providers and payers," said Adam Gale, KLAS President. "The Category Leader award carries with it the voice of thousands of providers and payers, highlighting outstanding vendors who have raised the bar."

For a full copy of the most recent KLAS report, please go here.

About KLAS

KLAS is a data-driven company on a mission to improve the world's healthcare by enabling provider and payer voices to be heard and counted. Working with thousands of healthcare professionals, KLAS collects insights on software, services and medical equipment to deliver reports, trending data and statistical overviews. KLAS data is accurate, honest and impartial. The research directly reflects the voice of healthcare professionals and acts as a catalyst for improving vendor performance. To learn more about KLAS and the insights we provide, visit www.KLASresearch.com.

About Elsevier

Elsevier is a global information analytics business that helps institutions and professionals advance healthcare, open science and improve performance for the benefit of humanity. Elsevier provides digital solutions and tools in the areas of strategic research management, R&D performance, clinical decision support and professional education, including ScienceDirect, Scopus, SciVal, ClinicalKey and Sherpath. Elsevier publishes over 2,500 digitized journals, including The Lancet and Cell, 38,000 e-book titles and many iconic reference works, including Gray's Anatomy. Elsevier is part of RELX Group, a global provider of information and analytics for professionals and business customers across industries. www.elsevier.com

Media contact

Christopher Capot, Global Communications
Elsevier
+1-917-704-5174
c.capot@elsevier.com

© 2019 PR Newswire
Zeitenwende! 3 Uranaktien vor der Neubewertung
Ende Mai leitete US-Präsident Donald Trump mit der Unterzeichnung mehrerer Dekrete eine weitreichende Wende in der amerikanischen Energiepolitik ein. Im Fokus: der beschleunigte Ausbau der Kernenergie.

Mit einem umfassenden Maßnahmenpaket sollen Genehmigungsprozesse reformiert, kleinere Reaktoren gefördert und der Anteil von Atomstrom in den USA massiv gesteigert werden. Auslöser ist der explodierende Energiebedarf durch KI-Rechenzentren, der eine stabile, CO₂-arme Grundlastversorgung zwingend notwendig macht.

In unserem kostenlosen Spezialreport erfahren Sie, welche 3 Unternehmen jetzt im Zentrum dieser energiepolitischen Neuausrichtung stehen, und wer vom kommenden Boom der Nuklearindustrie besonders profitieren könnte.

Holen Sie sich den neuesten Report! Verpassen Sie nicht, welche Aktien besonders von der Energiewende in den USA profitieren dürften, und laden Sie sich das Gratis-PDF jetzt kostenlos herunter.

Dieses exklusive Angebot gilt aber nur für kurze Zeit! Daher jetzt downloaden!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.